223 related articles for article (PubMed ID: 15746676)
1. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
[TBL] [Abstract][Full Text] [Related]
2. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
Togami S; Sasajima Y; Oi T; Ishikawa M; Onda T; Ikeda S; Kato T; Tsuda H; Kasamatsu T
Cancer Sci; 2012 May; 103(5):926-32. PubMed ID: 22329832
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
5. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
6. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
8. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
9. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
14. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
15. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
16. Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients.
Mandato VD; Torricelli F; Palomba S; Uccella S; Pirillo D; Ciarlini G; De Iaco P; Lucia E; Giorda G; Ditto A; Ghezzi F; Sanseverino F; Franchi M; Bifulco G; Mastrofilippo V; Abrate M; Aguzzoli L; La Sala GB
Am J Clin Oncol; 2019 May; 42(5):472-480. PubMed ID: 30973371
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
18. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
[TBL] [Abstract][Full Text] [Related]
19. CD44 expression in papillary serous endometrial carcinoma.
Hosford S; Elliott J; Ma ZW; Majeste R; Dubeshter B
Int J Gynecol Cancer; 2003; 13(4):480-4. PubMed ID: 12911725
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Tymon-Rosario J; Siegel ER; Bellone S; Harold J; Adjei N; Zeybek B; Mauricio D; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Azodi M; Schwartz PE; Fader AN; Santin AD
Gynecol Oncol; 2021 Oct; 163(1):93-99. PubMed ID: 34372971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]